Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

Eli Lilly's tirzepatide showed significantly greater weight loss than Novo Nordisk's semaglutide in a 72-week clinical trial ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and ...

A weight-loss trial of the two drugs found one clear winner. In case you’re not totally clued up, Wegovy is just a different ...

Both the Mounjaro and Wegovy jabs used in the trial were found to be effective treatments for patients with obesity, but one ...

WGN’s Dina Bair has the latest on new medical information, including: Study: Mounjaro helped people achieve more weight loss ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

Mounjaro, manufactured by US drugmaker, and Wegovy by Danish drugmaker Novo Nordisk, cause weight loss by suppressing the ...

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...